Effects of a Ketogenic and Low Fat Diet on the Human Metabolome, Microbiome and Food-ome in Adults at Risk for Alzheimer’s Disease - Dilmore, Amanda Hazel; Martino, Cameron; Neth, Bryan J.; West, Kiana A.; Zemlin, Jasmine; Rahman, Gibraan; Panitchpakdi, Morgan; Meehan, Michael J.; Weldon, Kelly C.; Blach, Colette; Schimmel, Leyla; Kaddurah-Daouk, Rima; et al. (medRxiv, 2022)
INTRODUCTION The ketogenic diet (KD) is an intriguing candidate for neuroprotection in Alzheimer’s disease (AD) given its protective effects against metabolic dysregulation and seizures. The diet’s neuroprotective effects have been shown to be gut microbiome-dependent in mice; thus we examined KD-induced changes in the gut microbiome and metabolome in patients at-risk for AD.METHODS We compared the low-carbohydrate modified Mediterranean Ketogenic Diet (MMKD) to the low-fat American Heart Association Diet (AHAD) in adults with mild cognitive impairment (MCI) and control participants. We collected stool samples for shotgun metagenomics and untargeted metabolomics at five timepoints to interrogate the microbiome and metabolome.RESULTS Individuals with MCI on the MMKD had lower levels of GABA-producing microbes Alistipes sp. CAG:514 and GABA, and higher levels of GABA-regulating microbes Akkermansia muciniphila.DISCUSSION We hypothesize that MMKD protects individuals with MCI in part via influencing on GABA levels and gut-transit time.Competing Interest StatementR.K-D. is an inventor of key patents in the field of Metabolomics and holds equity in Metabolon, a biotech company in North Carolina. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership, which is unrelated to this work. P.C.D. is on the scientific advisory board of Sirenas, Cybele Microbiome, Galileo, and founder and scientific advisor of Ometa Labs LLC and Enveda (with approval from UC San Diego).Clinical TrialNCT02984540Funding StatementThis work was supported by the Wake Forest Alzheimer's Disease Research Center (P30-AG072947), the Hartman Family Foundation, and the Roena B. Kulynych Center for Memory and Cognition Research. Funding for the AGMP (Alzheimer's Gut Microbiome Project) and ADMC (Alzheimer's Disease Metabolomics Consortium), led by Dr R.K.-D. at Duke University) was provided by the National Institute on Aging grants 5U19AG063744, 31U01AG061359-01, 1RF1AG059093, 1RF1AG057452, and R01AG046171, a component of the Accelerating Medicines Partnership for AD (AMP-AD) Target Discovery and Preclinical Validation Project (https://www.nia.nih.gov/research/dn/amp-ad-target-discovery-and-preclinical-validation-project) and the National Institute on Aging grant RF1 AG0151550.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Wake Forest Institutional Review Board (ClinicalTrials.gov Identifier: NCT02984540), and written informed consent was obtained from all participants and/or their study partners. Participants were medically supervised by clinicians, with safety monitoring overseen by the Wake Forest Institutional Data and Safety Monitoring Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMetagenomic sequencing data are available in Qiita under study ID 13662. Mass spectrometry data (.mzXML format) are available in MassIVE under ID MSV000087087. The classical molecular networking job is available in GNPS at the following link: https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=90f1ba6e1e4d4d89b75b9017a0631983. The feature-based molecular networking job is available in GNPS at the following link: https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=16e7c66221ce4ae9ae6678ec276d8343. The code utilized for these analyses are available at https://github.com/ahdilmore/BEAM_MultiOmics. https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=90f1ba6e1e4d4d89b75b9017a0631983 https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=16e7c66221ce4ae9ae6678ec276d8343 https://github.com/ahdilmore/BEAM_MultiOmics